Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

40.48
-0.1200-0.30%
Post-market: 40.480.00000.00%19:30 EDT
Volume:1.29M
Turnover:52.21M
Market Cap:4.40B
PE:-21.88
High:41.46
Open:40.39
Low:39.86
Close:40.60
52wk High:48.51
52wk Low:14.25
Shares:108.60M
Float Shares:88.17M
Volume Ratio:0.62
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8502
EPS(LYR):-1.6302
ROE:-38.03%
ROA:-25.03%
PB:9.81
PE(LYR):-24.83

Loading ...

Edgewise Therapeutics Grants Inducement Equity Awards Covering 11,251 Shares to Three New Employees

Reuters
·
Yesterday

Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules

THOMSON REUTERS
·
Yesterday

Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says

MT Newswires Live
·
Sep 26

Edgewise Therapeutics Down over 9%, on Pace for Largest Percent Decrease Since December 2025

Dow Jones
·
Sep 24

Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says

MT Newswires Live
·
Sep 23

Edgewise Therapeutics (EWTX) Gets a Buy from RBC Capital

TIPRANKS
·
Sep 23

Edgewise Therapeutics Details Preclinical Profile of EDG-7500 Cardiac Sarcomere Modulator in Hypertrophic Cardiomyopathy

Reuters
·
Sep 22

Edgewise Therapeutics Price Target Raised to $57.00/Share from $45.00 by HC Wainwright & Co.

Dow Jones
·
Sep 21

US Research Roundup-eBay, Sunbelt Rentals, T-Mobile

Reuters
·
Sep 21

Edgewise Therapeutics Grants Inducement Equity Awards Covering 31,501 Shares to New Hires

Reuters
·
Sep 02

Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules

THOMSON REUTERS
·
Sep 02

Goldman Sachs Sticks to Their Hold Rating for Edgewise Therapeutics (EWTX)

TIPRANKS
·
Sep 01

Edgewise Therapeutics (EWTX) Receives a Buy from RBC Capital

TIPRANKS
·
Aug 31

Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy

Reuters
·
Aug 24

Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision

TIPRANKS
·
Aug 21

Edgewise Therapeutics Price Target Raised to $60.00/Share from $53.00 by JP Morgan

Dow Jones
·
Aug 21

Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan

TIPRANKS
·
Aug 20

Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?

Simply Wall St.
·
Aug 20

Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich

Simply Wall St.
·
Aug 17

Edgewise Therapeutics CMO Joanne M. Donovan Disposes of USD 411,192 in Common Shares

Reuters
·
Aug 15